Cavion is developing oral small molecules designed to selectively modulate T-type calcium channel activity in the central nervous system, acting as a biological "pacemaker" to help restore the brain's natural rhythms.
The company's lead candidate CX-8998 is a first-in-class T-type calcium channel modulator and is the most advanced late-stage small molecule currently in development for essential tremor.
CX-8998 was evaluated in the T-CALM Study, a Phase 2, double-blind, placebo-controlled clinical trial of 95 patients with essential tremor conducted at 25 sites across the United States.
Patients were randomised to one of two treatment arms, receiving either placebo or CX-8998. A majority of subjects took study drug on top of certain standard of care anti-tremor medications.
Cavion is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.
The company's portfolio of T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.
About 10m Americans and 42 m people worldwide are affected by essential tremor, the most common movement disorder.
ET is a progressive neurodegenerative disease that ranges from mild to fully debilitating, with significant effects on people's quality of life and activities of daily living, such as eating and drinking, dressing, writing and typing.
The condition can lead to social embarrassment, phobia, anxiety, and depression.
With no new drugs approved for more than three decades, there is a need for new and effective options for patients with ET.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference